With so many biologics in development and no patient-centric way to deliver them, it was inevitable that innovative delivery solutions would emerge that enable a new pharmaceutical product to meet two top criteria for successful commercialization: satisfy patient demands for easy drug administration without disruption to their everyday lives, and address health system demands for lower costs and more value. The solution lies in combining biologic drugs with the more advanced large volume wearable injectors to enable patients to self-inject even the most viscous formulations and volumes of up to 50 mL with ease and comfort in their homes or workplaces.
Pharmaceutical companies to accelerate investment in patient-centric capabilities and services over next two years, according to Accenture report [press release]. Published April 12, 2016. https://newsroom.accenture.com/news/pharmaceutical-companiesto-accelerate-investment-in-patient-centric-capabilities-and-services-over-next-two-yearsaccording-to-accenture-report.htm.
Bolus Injectors Market, 2014-2024, November 2013 – Roots Analysis Private Ltd
Medicines in development – Biologics http://pharma.org/sites/default/files/pdf/biologics2013.pdf
D. Gilbert and & D. Cothran, "SC versus IV Delivery: Reducing Costs while Increasing Patient Satisfaction," Hematology & Oncology News & Issues, Dec. 25–27, 2005
J. Prettyman, "Subcutaneous or Intramuscular? Confronting a Parenteral Administration Dilemma," Medsurg. Nursing, 14 (2), 93–98 (2005).
H.C. Ansel, L.V. Allen, and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams & Wilkins, Philadelphia, PA, 8th ed., 2004).
Collins, M. “Here’s What’s Important About Alder Biopharmaceuticals’ Latest Release”. Market Exclusive, July 26, 2016
Burgess, BE, “Optimizing Drug Delivery for Modern Biologics”. BioPharm Int, 2012, Vol 25 (5).
Doughty D, Clawson CZ, Lamber W, et al., “Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery.” J Pharm Sci, 2016, Vol 105, pp 2105-2113.
Rule S et al. “Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom”. J Med Econ, 2014, Vol 17(7), pp 459-468.
Škalko-Basnet N, “Biologics: the role of delivery systems in improved therapy”, Biologics, 2014, Vol 8, pp 107-114.
Palm T, Sahin E, Gandi R, et al, “The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics”, BioProcess Int, March 10, 2015.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).